Project Grant R01DK144511
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Washington University $277,506 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), a K01 Mentored Career Development Award supporting research into cytoskeletal regulation of gut tube organogenesis and maturation of stem cell-derived islets. The award funds a career development training plan designed to transition the candidate to an independent...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $578,846 on February 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate brown adipose tissue–derived nidogen-2 as a potential diabetes therapeutic. The research addresses hyperglycemia and hypoglycemia risks in type 1 and advanced type 2 diabetes. Preliminary data show that nidogen-2, a secreted protein isolated from brown...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Washington University $720,353 on March 25, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847, Assistance Listing Project Grant R01DK141555). The award funds research to identify and elucidate the functioning of hypothalamic neural circuits that regulate energy balance and metabolism, with focus on obesity-associated metabolic diseases. The research targets a...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $158,554 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds research investigating the role of ATP-sensitive potassium (KATP) channels in type 2 diabetes mellitus development. The project will examine mouse models of type 2 diabetes and human diabetic subjects to probe potential alterations in KATP channel activity...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $537,032 on July 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support research on palmitoylation and type 2 diabetes through March 31, 2031. The project investigates the role of protein S-palmitoylation in beta cell dysfunction underlying type 2 diabetes. The research focuses on acyl-protein thioesterase 1 (APT1), an enzyme that...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $610,628 on May 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate phosphatidylserine as a signaling molecule during cellular differentiation. The research examines phosphatidylserine exposure on preadipocytes and its role in regulating adipocyte differentiation. The project tests whether phosphatidylserine exposure on live...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The University of Chicago $123,000 on June 16, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to characterize adipocyte heterogeneity and response to metabolic stress. The funded research uses single-nucleus RNA sequencing and a humanized mouse model to investigate how diverse stimuli influence white adipocyte development and specification, with emphasis on...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Delphi Stem, Inc. $306,863 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a framework for evaluating type 2 diabetes medication efficacy using patient-derived cellular models. The recipient will generate personalized islet-like aggregates from patient cells to predict drug responsiveness and tailor treatment regimens, with the goal of improving...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), an institute of the Department of Health and Human Services National Institutes of Health, awarded $795,620 to the University of Massachusetts Medical School on July 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds development and validation of gene-editing technologies to engineer stem cell-derived islets for type 1 diabetes treatment. The research...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $388,750 on April 23, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the structural and functional mechanisms of podocin in glomerular membrane organization and kidney disease. The research applies detergent-free, vesicle-based cryo-electron microscopy to determine the full-length structure of podocin at near-atomic resolution...
The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $764,322 on August 10, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847, Project Grant R01DK144511). The award funds development of induced pluripotent stem cell (iPSC) modeling platforms to investigate partial lipodystrophy syndromes, a group of rare disorders characterized by regional loss of white adipose tissue that leads to insulin resistance, diabetes, and dyslipidemia. The research will test and compare two iPSC approaches: reprogramming patient-derived peripheral blood mononuclear cells with genetic variant correction via CRISPR/Cas9, and introducing multiple variants into wild-type iPSC lines for consistency and high-throughput screening. The work will focus on five patients with partial lipodystrophy harboring potentially pathogenic variants. Successful completion will identify novel genetic causes of partial lipodystrophy, elucidate disease pathophysiology, resolve methodological debates about optimal modeling strategies, and establish a platform for therapeutic compound screening to support personalized cellular therapies. Performance occurs in St. Louis, Missouri, with work extending through April 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $764.3k | 8/10/26 |